Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NBQ72S in Breast Cancer Patients With Leptomeningeal Metastases
NCT06810804Phase 2Recruiting
- Sponsor
- Nantong Bencao Quadriga Medical Technology Co. Ltd.
- Start
- Apr 2025
- Primary completion
- Aug 2026
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of QBS10072S in breast cancer, sponsored by Nantong Bencao Quadriga Medical Technology Co. Ltd. Primary endpoint: Overall Survival at 1.5 years. Started Apr 2025; status: recruiting.
02
Drugs
QBS10072S
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06810804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06810804.